Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction

被引：2
作者：
Packer, Milton [1 ,2 ]
Cleland, John G. F. [3 ]
Bauersachs, Johann [4 ]
机构：
[1] Baylor Heart & Vasc Inst, Dallas, TX USA
[2] Imperial Coll, London, England
[3] Univ Glasgow, British Heart Fdn Ctr Res Excellence, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland
[4] Hannover Med Sch, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷 / 25期
关键词：
Heart failure; SGLT2; inhibitor; Pharmacotherapy; Foundational drugs; Hospitalization; EMPAGLIFLOZIN; RISK; DAPAGLIFLOZIN; HYPERTENSION; METAANALYSIS; DIURETICS; MORTALITY; MEDICINE; BENEFITS; OUTCOMES;
D O I：
10.1093/eurheartj/ehae300
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Graphical Abstract SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction. ARNI, angiotensin receptor-neprilysin inhibitor; CV, cardiovascular; GRMT, guideline-recommended medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose cotransporter 2 inhibitor.
引用
收藏
页码：2186 / 2196
页数：11
相关论文
共 50 条
  • [21] SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis
    Banerjee, Mainak
    Pal, Rimesh
    Nair, Kirthana
    Mukhopadhyay, Satinath
    INDIAN HEART JOURNAL, 2023, 75 (02) : 122 - 127
  • [22] Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes
    Theofilis, Panagiotis
    Sagris, Marios
    Oikonomou, Evangelos
    Antonopoulos, Alexios S.
    Siasos, Gerasimos
    Tsioufis, Kostas
    Tousoulis, Dimitris
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 188
  • [23] Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction
    Docherty, Kieran F.
    McMurray, John J. V.
    Kalra, Paul R.
    Cleland, John G. F.
    Lang, Ninian N.
    Petrie, Mark C.
    Robertson, Michele
    Ford, Ian
    ESC HEART FAILURE, 2024, 11 (04): : 1875 - 1879
  • [24] Do sglt2 inhibitors improve survival in heart failure with any ejection fraction?
    Yi, Ko
    Wong, Suzanne
    Wong, Kenneth
    Al-riyahi, Mohammad
    HEART, 2023, 109 : A175 - A177
  • [25] Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction
    Mouhamed Nashawi
    Omar Sheikh
    Ayman Battisha
    Mahnoor Mir
    Robert Chilton
    Heart Failure Reviews, 2022, 27 : 219 - 234
  • [26] Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
    Rebecca Heath
    Håkon Johnsen
    W. David Strain
    Marc Evans
    Diabetes Therapy, 2022, 13 : 241 - 250
  • [27] Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction
    Nashawi, Mouhamed
    Sheikh, Omar
    Battisha, Ayman
    Mir, Mahnoor
    Chilton, Robert
    HEART FAILURE REVIEWS, 2022, 27 (01) : 219 - 234
  • [28] SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction
    Hias, Julie
    Hellemans, Laura
    Walgraeve, Karolien
    Tournoy, Jos
    Van der Linden, Lorenz
    DRUGS & AGING, 2022, 39 (03) : 185 - 190
  • [29] Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
    Xie, Yafei
    Wei, Yujie
    Li, Dan
    Pu, Jie
    Ding, Hong
    Zhang, Xiaowei
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2023, 81 (01) : 4 - 14
  • [30] Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review
    Jhalani, Nisha B.
    ADVANCES IN THERAPY, 2022, 39 (08) : 3472 - 3487
12345